| (Values in U.S. Thousands) | Mar, 2026 | Mar, 2025 | Mar, 2024 | Mar, 2023 | Mar, 2022 |
| Sales | 4,195 | 4,944 | 4,752 | 3,950 | 2,326 |
| Sales Growth | -15.15% | +4.05% | +20.31% | +69.84% | +1,995.96% |
| Net Income | -6,102 | -4,042 | -7,627 | -5,398 | -14,367 |
| Net Income Growth | -50.96% | +47.00% | -41.29% | +62.43% | -773.47% |
Rhelion Life Sciences Corp (RHEL.CN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [CNSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Rhelion Life Sciences Corp is a pharmaceutical research and development company focused on the discovery and development of natural psychedelic medicines for psychiatric and neurological conditions.
Fiscal Year End Date: 03/31